Health Economic Evaluation of Human Papillomavirus Vaccination for Age- Eligible Females in Guangxi: An Analysis Based on the PRIME Model
Based on the 2025 PRIME model analysis, implementing a free HPV vaccination program for 13-year-old girls in Guangxi using the domestic bivalent vaccine is a cost-saving strategy that yields a benefit-cost ratio of nearly 5:1, while the domestic 9-valent vaccine also proves highly cost-effective, supporting the acceleration of these immunization initiatives.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Imagine the human body as a bustling city, and the immune system as its tireless police force. Sometimes, a sneaky intruder called the Human Papillomavirus (HPV) slips past the guards. While most of these intruders are harmless tourists who leave quickly, a few are dangerous criminals that can cause trouble years later, specifically by turning healthy cells into cancer. One type of cancer, cervical cancer, is like a slow-burning fire in a specific neighborhood of the city. The good news is that we have a "shield" called a vaccine. Think of the vaccine as a wanted poster given to the police before the criminals even arrive; it teaches the immune system exactly what the bad guys look like so they can be stopped instantly.
For a long time, these shields were expensive and hard to get for many people, especially in poorer areas. But recently, the price of these shields has dropped dramatically, and some governments are now offering them for free. This raises a big question for the people who manage the city's budget: Is it worth spending money on these shields now? To answer this, scientists use a tool called a "health economic evaluation." It's like a super-advanced calculator that compares the cost of buying the shields against the massive cost of putting out the fire later if the cancer starts. They also use a model called PRIME, which is a computer simulation that acts like a time machine, predicting what happens to a group of girls over their entire lives to see if the vaccine saves money and lives in the long run.
This study zooms in on Guangxi, a region in southwestern China, to see if giving free HPV vaccines to 13-year-old girls makes financial sense under the brand-new, super-low prices available in 2025. The researchers ran their time-machine simulation using the latest local data and found a result that sounds almost too good to be true: vaccinating these girls isn't just a good idea; it's a money-saver.
Here is the story of what they found. The team simulated a scenario where the government buys a specific type of shield—the domestic bivalent vaccine—at a new, incredibly low price of 27.5 RMB per dose. They imagined vaccinating 70% of the 13-year-old girls in Guangxi. When they crunched the numbers, the simulation showed that for every 1 RMB spent on the vaccine, the city would save nearly 5 RMB in future medical bills for treating cervical cancer. In fact, the total cost of the vaccination program was so low compared to the money saved on cancer treatment that the program actually ended up with a "negative cost." It's like buying a fire extinguisher for a few dollars and saving thousands of dollars in fire damage; you end up with more money in your pocket than when you started.
The researchers didn't just look at the cheapest shield. They also simulated using a more advanced shield called the domestic 9-valent vaccine, which protects against more types of the virus. This one costs 531 RMB per dose. While it doesn't save money in the same way the cheaper one does, the simulation showed it is still an excellent deal. For every year of healthy life saved by using this vaccine, the cost is only half of what a person in Guangxi earns in a year on average. This is considered "very cost-effective," meaning it's a smart investment even if it doesn't immediately put cash back in the bank.
The study also tested the "what-if" scenarios to see if their conclusion would hold up if things changed. What if the vaccine price went up a little? What if the treatment for cancer became cheaper? What if fewer girls got vaccinated? The computer simulation showed that no matter how they tweaked the numbers, the cheap domestic bivalent vaccine remained a money-saver. It was so robust that even if they cut the cost of cancer treatment in half or changed the discount rate, the vaccine still saved money. This suggests the finding is very strong and not just a lucky guess.
However, the paper does point out a few things to keep in mind. The simulation assumes the vaccine works perfectly forever, which is a simplification; in the real world, we need to keep watching to see how long the protection lasts. Also, the model didn't count the extra benefits of the vaccine against other types of cancers, meaning the real-world savings might be even higher than the simulation suggests. The study also notes that while the simulation is great, it doesn't account for how the vaccine might stop the virus from spreading from person to person (herd immunity), which could make the real-world benefits even bigger.
So, what is the bottom line for the people running the show in Guangxi? The simulation strongly suggests that the best move right now is to roll out the free vaccination program immediately using the cheap domestic bivalent vaccine. This strategy will save the healthcare system a fortune and prevent thousands of cases of cancer. Once that is up and running, and if the budget allows, they could consider switching to the more advanced domestic 9-valent vaccine to protect against even more types of the virus. The paper concludes that waiting around isn't necessary; with these new prices, the math says that vaccinating girls now is a win for both their health and the wallet.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.